Intercept Pharmaceuticals (ICPT) Settlement Removes Minor Overhang - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq set for lower open as AI stocks slide on debt concerns
- U.S. producer prices rise by 1.3% month-on-month in September
- Oil prices slips as US weighs easing sanctions on 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Walmart stock: Deutsche Bank gets bullish amid pricing tailwinds
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Intercept Pharma (ICPT) Enters Settlement of Proposed Class Action Suit
May 3, 2016 6:32 AM EDTIntercept Pharma (NASDAQ: ICPT) disclosed the following on Tuesday morning:
Item 8.01 Other Events
On May 2, 2016, Intercept Pharmaceuticals, Inc. (Intercept or the Company) reached an agreement with the lead plaintiff to seek Court approval of a proposed resolution of class action litigation pending against it in the U.S. District Court for the Southern District of New... More



